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Abstract
Antibodies to platelet endothelial cell adhesion molecule-1 (PECAM-1) facilitate targeted drug delivery to endothelial cells
by ‘‘vascular immunotargeting.’’ To define the targeting quantitatively, we investigated the endothelial binding of
monoclonal antibodies (mAbs) to extracellular epitopes of PECAM-1. Surprisingly, we have found in human and mouse cell
culture models that the endothelial binding of PECAM-directed mAbs and scFv therapeutic fusion protein is increased by
co-administration of a paired mAb directed to an adjacent, yet distinct PECAM-1 epitope. This results in significant
enhancement of functional activity of a PECAM-1-targeted scFv-thrombomodulin fusion protein generating therapeutic
activated Protein C. The ‘‘collaborative enhancement’’ of mAb binding is affirmed in vivo, as manifested by enhanced
pulmonary accumulation of intravenously administered radiolabeled PECAM-1 mAb when co-injected with an unlabeled
paired mAb in mice. This is the first demonstration of a positive modulatory effect of endothelial binding and vascular
immunotargeting provided by the simultaneous binding a paired mAb to adjacent distinct epitopes. The ‘‘collaborative
enhancement’’ phenomenon provides a novel paradigm for optimizing the endothelial-targeted delivery of therapeutic
agents.
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Introduction
Drug targeting to endothelial cells (ECs) (i.e., ‘‘vascular
immunotargeting’’) has the potential to improve management of
diseases involving ischemia, inflammation, thrombosis, and tumor
growth [1–5]. In particular, conjugation of therapeutics with
antibodies to PECAM-1 (platelet endothelial cell adhesion
molecule 1, CD31) enables their endothelial delivery, boosting
specificity and efficacy of their action in animal models [3,6].
Further optimization of this promising approach is warranted to
support translation into the clinical domain.
PECAM-1, a 130-kDa glycoprotein with six extracellular Ig-like
domains, a transmembrane domain and a cytoplasmic tail
(Figure S1), is present at modest levels on platelets and leukocytes
[7], and is highly expressed on ECs (10
6 copies per cell) [7,8].
Endothelial PECAM-1 molecules engage in trans (i.e., antiparallel)
homophilic interactions at intercellular junctions via distal Ig-like
domain 1 (IgD1) and domain 2 (IgD2) [9,10], and are involved in
maintenance of EC monolayer integrity [11], mechanosensing
[12], and cellular signaling [13]. Endothelial PECAM-1 also
facilitates leukocyte migration via homophilic and heterophilic
interactions with leukocytic PECAM-1 and other binding ligands
[14].
Monoclonal antibodies (mAbs) directed to different extracellular
epitopes and domains of PECAM-1 have been used as probes to
study the role of PECAM-1 in mediating homophilic and
heterophilic binding interactions [9,10,15–18], as well as affinity
ligands for endothelial targeting of drugs, and nanocarriers [3,19–
21]. Antibodies directed to distinct PECAM-1 epitopes have
different functional effects, either inhibiting, augmenting, or
having no effect on the IgD1/IgD2-mediated homophilic binding
interactions of PECAM-1 [17,22]. Further, the engagement of
specific PECAM-1 epitopes controls the rate of endothelial
internalization and intracellular trafficking of nanocarriers target-
ed by PECAM-1 mAbs [23]. These results suggest that
optimization of immunotargeting and intracellular delivery is
possible through the engagement of distinct PECAM-1 epitopes.
In the present study we set out to investigate the in vitro and in
vivo binding parameters of mAbs directed to the IgD1 and IgD2
domains of PECAM-1 and address mutual effects of their binding.
The latter aspect is a relatively uncharted one in vascular
immunotargeting. Studies in this area are limited to mAbs to
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34958angiotensin-converting enzyme (ACE), a promising molecular
target for drug delivery to endothelium [24,25], and show that
anti-ACE mAbs directed to distinct epitopes negatively mutually
interfere with binding of each other [26].
However, in contrast with this somewhat expected outcome
with anti-ACE mAbs, our results indicate that endothelial
immunotargeting of anti-PECAM-1 mAb can be significantly
enhanced by the simultaneous binding of paired mAbs directed to
adjacent, yet distinct PECAM-1 epitopes in both in vitro cell culture
and in vivo mouse studies. Motivated by this hugely unusual
outcome, we set out to determine whether augmentation in
binding translates to an increase in therapeutic protein delivery
and functional output. We used a therapeutic fusion protein
targeted to PECAM-1 to demonstrate that enhanced delivery
results in a significant increase in the fusion-catalyzed generation
of a cell-protective species with antithrombotic and anti-inflam-
matory activities. This antibody-dependent ‘‘collaborative en-
hancement’’ phenomenon illustrates the potential of this targeting
strategy for increasing the efficiency of vascular delivery in
therapeutic applications.
Results
Characterization of in vitro PECAM-1 interactions with
mAbs
Epitope mapping has shown that mAbs 62 and 37 bind to
distinct epitopes in IgD1 in human PECAM-1 (huPECAM-1) [22],
and mAbs 390 and MEC13.3 bind to their respective non-
overlapping epitopes in IgD2 of the murine homolog, muPECAM-
1 (H. DeLisser, unpublished results; Figure 1). The specificity and
sensitivity of these mAbs for binding to PECAM-1 was confirmed
by live-cell ELISA using confluent monolayers of human
endothelial cells (human umbilical vein endothelial cells (HU-
VECs)) and human endothelial-like REN cells stably expressing
recombinant muPECAM-1 (REN-muP) [27]. In these cell culture
models, most of surface PECAM-1 molecules are involved in trans-
homodimeric interactions at intercellular borders [28–30]. ELISA
showed that unmodified anti-PECAM mAbs specifically bind to
ECs at nanomolar levels, albeit with considerable differences in
binding, as reflected by IC50 (Figure 2). In HUVECs, mAb 62
binding is ,52fold weaker vs mAb 37 binding (IC50=1.59 nM vs
0.34 nM) (Figure 2C). Further, mAb MEC13.3 binding to REN-
muP cells (IC50=2.43 nM) is 272fold weaker than the mAb 390
binding (IC50=0.09 nM) (Figure 2C). The binding of mAb
MEC13.3 is 122fold lower than mAb 390 to MS1 cells expressing
native muPECAM-1 (Figure 2C, Figure S2).
Live-cell radioimmunoassay (RIA) of
125I-labeled mAbs ([
125I]-
mAb) was used for quantitative assessment of equilibrium binding
parameters (Kd), including the number of maximum available
binding sites (Bmax). Analysis of [
125I]-mAb binding to HUVECs
by RIA yielded Kd of 4.32 nM and 0.24 nM for [
125I]-mAb 62
and [
125I]-mAb 37, respectively (corresponding Bmax values are
2.6610
5 mAb/cell and 1.5610
5 mAb/cell) (Figure 3A). [
125I]-
MAb 390 and [
125I]-mAb MEC13.3 specifically bind to REN-
muP cells with Kd 0.07 nM and 0.45 nM, respectively (corre-
sponding Bmax values are 2.6610
5 mAb/cell and 4.1610
5 mAb/
cell) (Figure 3B). Similarly, [
125I]-mAb 390 and [
125I]-mAb
MEC13.3 specifically bind to MS1 ECs with Kd 0.25 nM and
2.81 nM, respectively, and with Bmax of mAb 390 also being
nearly twice lower that mAb MEC13.3 (Table S1).
Modulation of in vitro PECAM-1 targeting
We next investigated the mutual binding effects of mAb 37 and
62 to their epitopes in IgD1 of huPECAM-1. Expectedly,
endothelial binding of [
125I]-mAb 62 and [
125I]-mAb 37 was
competitively inhibited by their respective unlabeled mAb
counterparts directed to the same epitope (‘‘self-paired’’)
(Figure 4A; Figure S3). However, binding of [
125I]-mAb 62
was enhanced 1.52fold by unlabeled mAb 37 (‘‘paired’’)
(Figure 4A,B). This enhancement effect was not mutual, as
unlabeled mAb 62 did not alter the binding of [
125I]-mAb 37
(Figure S3). [
125I]-mAbs 62 and 37 bind to immobilized
huPECAM-1, but not to mAb pairs or control IgG (Figure S4).
This result confirms that modulation of anti-PECAM mAb
binding to endothelial cells is due to binding through cellular
PECAM-1 and not due to binding to cell-associated antibodies.
RIA of [
125I]-mAb 62 co-incubated with 50 nM enhancer mAb
37 with HUVEC revealed that the apparent binding affinity of
[
125I]-mAb62 is increased nearly 1.42fold (Kd
4.25 nMR2.96 nM, P,0.001) (Table S2). Furthermore, a
similar result is observed using wells coated with the soluble
extracellular domain of recombinant huPECAM-1: the apparent
binding affinity of [
125I]-mAb62 with mAb 37 co-treatment
increases nearly four2fold (Kd 4.77 nMR1.24 nM, P,0.001)
(Table S2). Taken together, these data suggest that the
Figure 1. Monoclonal antibody (mAb) ligands recognizing
distinct extracellular epitopes of PECAM-1. (A) MAbs investigated
in this study to probe the affinity and accessibility to distinct epitopes
of human PECAM-1 (huPECAM-1; mAbs 62 and 37) and mouse PECAM-1
(muPECAM-1; mAbs 390 and MEC13.3). Listed is the effect of various
anti-PECAM-1 mAbs on PECAM-1-dependent homophilic adhesion, as
defined by the aggregation of L-cells fibroblast transfectants expressing
PECAM-1 [22,50]. [15,22]. (B–C) Diagram of immunoreactive regions
within PECAM-1 domains 1 and 2. (B) Amino acid (AA) location of
distinct non-overlapping epitopes for binding of mAbs 62 and 37 on Ig-
domain 1 (IgD1) of huPECAM-1 [22]. (C) AA location of epitopes for
mAbs 390 and MEC13.3 on Ig-domain 2 (IgD2) of muPECAM-1 (H.
DeLisser, unpublished results). Peptide sequence recognized by mAbs
are colored in red.
doi:10.1371/journal.pone.0034958.g001
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125I]-mAb62 binding by an enhancer mAb, as
evidenced by changes in Kd and Bmax, is mediated specifically
through huPECAM-1 via collaborative enhancement. It remains
unclear at this time if the observed phenomenon is due to changes
in a single PECAM-1 molecule or changes in homodimeric
PECAM-1-PECAM-1 interactions.
To test whether the collaborative binding phenomenon is
unique to human PECAM-1, we investigated mAb modulatory
effects on muPECAM-1-expressing cells. Binding of [
125I]-mAb
390 and [
125I]-mAb MEC13.3 to REN-muP cells expressing
recombinant muPECAM-1 was inhibited by its unlabeled self-
paired mAb, yet enhanced by paired mAb directed to a distinct
muPECAM-1 epitope (Figure 4C). These results were recapitu-
lated in murine MS1 endothelial cells expressing native muPE-
CAM-1 (Figure S5). Interestingly, the most dramatic collabora-
tive enhancement was observed with the pairing of mAb 390
(Kd=0.07 nM) with [
125I]-mAb MEC13.3 (Kd=0.45 nM), re-
sulting in a 2.72fold increase in binding over [
125I]-mAb
MEC13.3 alone (Figure 4C,D). MAb MEC13.3, with its 62fold
lower affinity relative to mAb 390 was able to enhance [
125I]-mAb
390 binding up to 1.52fold above control uptake.
Collaborative enhancement increases targeting and
effect of a therapeutic fusion protein
Collaborative enhancement of anti-PECAM mAbs binding was
validated using a novel protein therapeutic prodrug, i.e., the
extracellular domain of mouse thrombomodulin (TM) fused to a
single-chain variable fragment (scFv) targeted to the 390 epitope of
muPECAM-1 (390 scFv-TM [31]). Live-cell ELISA demonstrated
that paired mAb MEC13.3 increased the apparent binding affinity
of 390 scFv-TM ,42fold relative to fusion alone (IC50 0.91 nM
vs. 3.49 nM) (Figure 5A). Self-pairing the epitope with maternal
mAb 390 inhibited 390 scFv-TM binding close to control levels
with REN cells. This increase in binding affinity is accompanied
by an increase in 390 scFv-TM bound to muPECAM-1, as made
apparent by a higher maximum OD490 value compared to 390
scFv-TM alone.
We further examined whether enhanced delivery of 390 scFv-
TM may have therapeutic consequences. TM captures the serine-
protease thrombin and modulates its pro-thrombotic activity to
convert protein C to activated protein C (APC), which itself has
cell-protective anti-thrombotic and anti-inflammatory effects [32].
Targeting of the TM fusion protein to the luminal endothelial
surface helps to control coagulation and inflammation in animal
Figure 2. In vitro binding properties of mAb to live cells expressing PECAM-1. Cell surface binding of mAbs to PECAM-1 was determined by
ELISA-based method with (A) HUVECs, (B) REN-muP cells. Proteins were added to confluent cellular monolayers at the indicated dilutions and
incubated for 2 h at 4uC. The results shown are from a representative experiment. Non-targeted IgG or non-PECAM-1 expressing cells were used as
negative control. Representative plots for mAb binding to MS1 cells are available in Figure S2.( C) Analysis of the relative binding affinity of anti-
PECAM-1 mAbs, when binding to cells is half-maximal (IC50). Data points were fit as described under ‘‘Methods.’’ The IC50 is reported as the mean IC50
value 6 SD of three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0034958.g002
Collaborative mAb Binding to Endothelial PECAM-1
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e34958models of acute lung injury and ischemia/reperfusion via APC-
mediated pathways [3,31]. 390 scFv-TM bound to REN-muP
cells, which have no endogenous TM, generates APC from protein
C zymogen in the presence of thrombin. We found that REN-muP
cells co-incubated with 390 scFv-TM and MEC13.3 demonstrated
a ,62fold increase in APC generation relative to 390 scFv-TM
alone (Figure 5B). Moreover, pairing of mAb MEC13.3 with 390
scFv-TM seemed to shift the potency of the prodrug (based on
APC generation levels) to lower concentrations of 390 scFv-TM.
These observations closely parallel the ELISA results and indicates
an increase in both binding affinity and absolute fusion protein
bound.
Co-immunoprecipitation (co-IP) studies revealed formation of a
tri-molecular complex between 390 scFv-TM, PECAM-1 and
MEC13.3 mAb (Figure 5C, lane 8). The simultaneous binding
of the antibody ligands to adjacent non-overlapping epitopes of
PECAM-1 suggests that the increased binding and functional
effect of the fusion protein are mediated through modulation of its
interaction with PECAM-1 by the enhancing antibody.
In vivo PECAM-1 targeting
In vitro studies suggest that mAb-mediated modulation of
endothelial binding may have important implications for the
vascular immunotargeting using PECAM-1 antibodies. To
evaluate collaborative enhancement of immunotargeting in vivo
and recapitulate cell culture findings, we studied effects of non-
labeled mAbs on the pulmonary uptake of [
125I]-mAb 390 and
[
125I]-mAb MEC13.3 injected in mice (Figure 6). The pulmonary
vasculature, due to the privileged perfusion and extended
endothelial surface area [33], is the preferential target of mAbs
directed to PECAM-1 [3,6]. Pulmonary targeting of [
125I]-mAb
390 and [
125I]-mAb MEC13.3 alone was reconfirmed and
determined to be 67% ID/g and 41% ID/g, respectively
(Figure 6A,B). Subsequently, [
125I]-mAbs were co-administered
with self-paired or paired mAb, and the in vivo results recapitulated
cell culture findings. The pulmonary uptake of [
125I]-mAbs was
inhibited by co-injection of non-labeled self-paired mAb down to
levels observed with control [
125I]-IgG. Co-administration of
paired mAb led to 2.12fold and 1.92fold enhancement in the
pulmonary uptake of [
125I]-mAb 390 and [
125I]-mAb MEC13.3,
respectively (Figure 6C). Correcting pulmonary uptake levels for
residual blood activity yields a more accurate reflection of
collaborative enhancement due to active vascular immunotarget-
ing of anti-PECAM-1 mAb. As compared to [
125I]-mAbs alone
(Figure 6B), the lung:blood localization ratio for both muPE-
CAM-1 mAb pairs is enhanced 3.42fold over mAb alone
(Figure 6D).
Discussion
The binding of ligands, including antibodies to epitopes of
target molecules can block the delivery of ligands directed to the
same epitope, or potentially modulate (i.e., block or enhance) the
binding of ligands directed to secondary epitopes. Herein, we
examined the interaction of a panel of four monoclonal antibodies
(mAbs) directed to distinct extracellular epitopes of PECAM-1
domains IgD1 (human) and IgD2 (murine) (Figure 1) for
understanding and optimizing endothelial immunotargeting.
PECAM-1 mAb binding exhibits properties characteristic of
mAb-antigen interactions: high affinity and specificity contributed
by the steric complementarity between the antibody and antigen
surface (Figures 2, 3). Interestingly, for the mAbs evaluated it
was clear that not all epitopes are displayed on PECAM-1 equally.
In this study, we found that the mAb with higher affinity was
Figure 3. Binding parameters of anti-PECAM-1 [
125I]-mAbs to live cells expressing PECAM-1. Cell surface binding parameters (Kd and
Bmax)o f[
125I]-mAbs to PECAM-1 was determined by RIA-based method with (A) native huPECAM-1 on HUVECs, and (B) recombinant muPECAM-1 on
REN-muP cells. Serial dilutions of [
125I]-mAbs were added to confluent cellular monolayers and incubated for 2 h at 4uC. The results shown are from a
representative experiment, with the inset showing Scatchard plot of binding data. Note that total binding was corrected for NSB using 1002fold
excess of unlabeled mAb for HUVECs or using parent REN cells for REN-muP binding. (C–D)K d and Bmax Binding parameters are for [
125I]-mAbs to
huPECAM-1 and muPECAM-1 are listed. Results were determined by three independent RIA experiments performed in quadruplicate, with data
expressed as mean 6 SD.
doi:10.1371/journal.pone.0034958.g003
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(Figure 3B). Variable accessibility to different antibodies could
result from differences in: (1) masking of an epitope (e.g., due to
tertiary structure of Ig-like domain, or masking by protein
glycosylation and/or other components of the plasmalemma), (2)
protein associations (e.g., different cell surface distribution and/or
cytoskeletal associations), (3) membrane turnover of PECAM-1
sub-populations, or (4) Ab-induced shedding of PECAM-1
resulting in diminished epitope expression. However, Kd and
Bmax binding parameters can serve as valuable empiric criteria in
judiciously selecting the most effective ligand (i.e. high affinity and
accessibility) for therapeutic vascular immunotargeting to PE-
CAM-1.
It has been reported that specific mAbs to huPECAM-1 IgD1
augments IgD1-mediated trans-homophilic interactions between
adjacent PECAM-1 molecules [22]. Based on these observations,
it stands to reason that if the binding of one mAb to PECAM-1
can increase the binding to an adjacent PECAM-1 molecule, then
it may also increase binding of a second mAb directed to a
different epitope, particularly in those domains that are implicated
in homophilic PECAM-1 binding. Similar types of ‘‘enhanced
binding’’ phenomena, attributed to conformational changes
induced in the target molecule due to protein allostery [34–36],
have been reported with binding of multiple ligands to isolated
proteins [37], cells [38] and tissue homogenates [39]. We are
observing this unusual behavior for the first time with antibodies
directed to an endothelial determinant, specifically PECAM-1
which has demonstrated potential for vascular targeting of
therapeutics, including immunoconjugates [19,21,40], fusion
proteins [3,20,31], and nanocarriers [23].
The results presented in this report show that the binding of
certain mAbs to epitopes in PECAM-1 domains 1 and 2 enhances
the binding of a second paired mAb to a distinct epitope in the
same domain, both in vitro (Figures 4, 5, S3, S4) and in vivo
(Figure 6). However, not all mAb pairs exhibit ‘‘collaborative
enhancement’’ nor to the same degree. Augmentation of [
125I]-
mAb binding is most pronounced using the paired ‘‘enhancer
mAb’’ with a higher affinity for PECAM-1 (as is the case with mAb
37 and mAb 390). This observation is likely due to the fact that
lower affinity mAb have greater potential for affinity elevation,
Figure 4. Anti-PECAM-1 [
125I]-mAb binding in live cells is enhanced by paired mAb directed to adjacent PECAM-1 epitope. The
modulation of PECAM-1 binding was determined by co-incubation of [
125I]-mAb with indicated concentrations of unlabeled self-paired mAb or
paired mAb with cells for 2 h at 4uC. Binding data were plotted as [
125I]-mAb molecules bound per cell (mAb/cell) and data points were fit as
described under ‘‘Methods.’’ (A and B) Unlabeled mAb 62 competitively inhibits binding of [
125I]-mAb 62 to huPECAM-1 in HUVEC. However, mAb 37
enhances [
125I]-mAb 62 binding to huPECAM-1 in HUVEC by 1.52fold over binding of [
125I]-mAb 62 alone. Interestingly, mAb 62 does not enhance
the binding of [
125I]-mAb 37 (Figure S3). (C–D) Collaborative binding studies of mAbs 390 and MEC13.3 with REN-muP cells as described in panel A.
Unlabeled self-paired mAb 390 and mAb MEC13.3 competitively inhibit binding of [
125I]-mAb390 and [
125I]-mAb MEC13.3 to REN-muP cells,
respectively. In contrast, mAb pairs [
125I]-mAb 390/MEC13.3 and [
125I]-mAb MEC13.3/390 enhance binding by ,1.52fold and ,2.72fold, respectively,
over [
125I]-mAb alone (***, P,0.001, n=3–4).
doi:10.1371/journal.pone.0034958.g004
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enhancer mAb. The innocuous effect of lower affinity mAb 62 on
[
125I]-mAb 37 binding (Figure S3) further suggests that a higher
affinity mAb ligand drives the increase in total binding of a paired
mAb to PECAM-1.
Additional studies reveal that [
125I]-mAb affinity to PECAM-1
also increases in the presence of an enhancer mAb. This is
evidenced by the 1.52to242fold decrease in the apparent Kd
when [
125I]-mAb 62 is co-incubated with enhancer mAb 37 both
in live cells and with immobilized PECAM-1 (Table S2). An
increase in binding affinity is also implied in the left shift of the
ELISA binding curve of the therapeutic 390 scFv-TM fusion
construct targeted to the mAb 390 epitope of muPECAM-1 when
modulated with mAb enhancer MEC13.3
(IC50=3.49 nMR0.91 nM, P,0.001) (Figure 5A). We hypoth-
esized that the improved affinity combined with an enhancement
in absolute 390 scFv-TM anchored to the endothelium would
result in more efficient production of APC at sites of injury.
Indeed, in vitro studies reveal a significant increase in APC
generation of 390 scFv-TM paired with mAb MEC13.3 (,62fold,
P,0.001) at much lower fusion concentrations than 390 scFv-TM
alone (Figure 5B). The clinical and translational impact of these
findings in an in vivo model of lung injury is of great significance
and we are currently resolving this question.
Collaborative enhancement is only realized if there exists a
ternary complex comprised of the mAb-ligand, the enhancer
mAb-ligand, and PECAM-1; Co-IP experiments with 390 scFv-
TM demonstrate that there is a complex between 390 scFv-TM/
muPECAM-1/MEC13.3 mAb (Figure 5C). This lends further
support that enhanced mAb binding and increased production of
APC is mediated directly through modulation of PECAM-1
epitope engagement.
Importantly, the collaborative enhancement of muPECAM-1
immunotargeting in vivo was confirmed when measuring the
Figure 5. In vitro enhancement of binding, accessibility and therapeutic output of anti-PECAM-1 390 scFv-TM fusion protein via
dual epitope-engagement of muPECAM-1. (A) Cell surface binding of the therapeutic fusion protein 390 scFv-TM to REN-muP cells was
assessed in the presence of 200 nM self-paired parental mAb 390 or paired mAb MEC13.3 by ELISA. The curves shown are representative ELISA. Only
binding to REN-muP cells shown; there was no significant binding detected using control REN cells lacking muPECAM-1. Binding affinity of 390 scFv-
TM, reflected by IC50, increases 3.82fold when paired with MEC13.3. The IC50 is reported as the mean IC50 value 6 SD of three independent
experiments performed in triplicate. (B) Generation of activated protein c (APC), a cell-protective species, on the surface of REN-muP cells is initiated
by targeted binding of 390 scFv-TM (+thrombin). APC generation is augmented up to 52fold when 390 scFv-TM binding is enhanced with paired
mAb MEC13.3 compared to 390 scFv-TM alone. (C) Co-IP of the MEC13.3/muPECAM-1/390 scFv-TM-FLAG complex in REN-muP cells. REN-muP cells
were treated with muPECAM-1 targeted rat anti-mouse IgG MEC13.3 and anti-mouse 390 scFv-TM-FLAG combinations. Cell lysates were
immunoprecipitated with Protein G agarose beads to MEC13.3 and analyzed by SDS-PAGE and immunoblotting (IB) using anti-muPECAM-1, anti-
FLAG, and rat polyclonal anti-mouse antibodies, as described under ‘‘Methods.’’ For controls, REN-muP cells 6390 scFv-TM FLAG were incubated with
Protein G beads alone (lanes 1 and 5, 3 and 7). 390 scFv-TM-FLAG was only detected in the IP for REN-muP cells co-treated with MEC13.3 and 390
scFv-TM-FLAG (lane 6), indicating an interaction between MEC13.3 and 390 scFv-TM through muPECAM-1. Data are representative of two
independent experiments.
doi:10.1371/journal.pone.0034958.g005
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125I]-mAb 390 and [
125I]-mAb MEC13.3
delivered intravenously in mice (Figure 6). The results of in vivo
studies in mice highlight the difficulty in predicting unambiguously
the best mAb for in vivo immunotargeting based on in vitro mAb
affinity and epitope accessibility from ELISA and RIA. For
instance, following normalization of pulmonary uptake for residual
blood levels (localization ration, LR) there is only 1.42fold higher
endothelial selectivity of [
125I]-mAb 390 versus [
125I]-mAb
MEC13.3 (Figure 6B,P ,0.001). This is despite mAb 390
having ,6.42fold higher binding affinity, albeit a 22fold lower
epitope accessibility relative to mAb MEC13.3. Co-injection of
[
125I]-mAb with PECAM-1 non-self pairs led to 2.12fold and
1.92fold increase in [
125I]-mAb 390 and [
125I]-mAb MEC13.3
lung uptake, respectively compared to [
125I]-mAb alone (LR
reaches 3.42fold for both [
125I]-mAbs). The innocuous effect of
co-administration of muICAM-1 mAb YN1 with muPECAM-1
[
125I]-mAbs pulmonary uptake confirms that collaborative en-
hancement in vivo is specific for anti-PECAM-1 mAb non-self
pairs.
Our findings are consistent with a model in which an enhancer
mAb binds to PECAM-1 to mediate collaborative enhancement of
paired mAb binding via a single PECAM-1 molecule or through a
PECAM-1-PECAM-1 homodimer. An enhancer mAb may
influence intermolecular interactions between PECAM-1 mole-
cules in the endothelial plasmalemma in many ways, including
ligand-mediated disruption of homologous dimerization and
oligomerization, as has been described, for example, with VEGFR
[41], EGFR/HER2 receptors [42], and ACE [43,44]. It is known
that mAbs 62 and 390 can inhibit formation of homophilic
PECAM-1/PECAM-1 interactions [10,14,22], although it is not
clear if these mAbs can actually disrupt existing PECAM-1
homodimers. In theory, the binding of anti-PECAM mAbs might
illicit surface exposure of additional PECAM-1 copies via more
generalized EC activation involving cytoskeletal rearrangements
Figure 6. In vivo endothelial targeting of [
125I]-mAb to muPECAM-1 is enhanced by paired muPECAM-1 mAb. (A) Biodistribution of
anti-muPECAM-1 [
125I]-mAbs 390 and MEC13.3 (0.2 mg/mouse) 30 min post-injection. (B) Localization ratio (LR) of [
125I]-mAb pulmonary uptake
normalized to residual blood radioactivity (lung:blood), reflecting selectivity of PECAM-1-directed targeting to vascular endothelium. (C) Pulmonary
uptake of [
125I]-mAb 390 and [
125I]-mAb MEC13.3 in inhibited by co-injection of unlabeled self-paired mAb (30 mg/mouse) directed to the same
epitope. Co-injection of a paired mAb (30 mg/mouse) enhanced targeting of both [
125I]-mAb 390 and [
125I]-mAb MEC13.3 by 2.12 and 1.92fold,
respectively. The dashed red line indicates the level of non-specific [
125I]-IgG uptake in the lungs. (D) Lung:blood LR for [
125I]-mAb 390/mAb MEC13.3
and [
125I]-mAb MEC13.3/mAb 390 pairs increases 3.42fold. The dotted red line is the LR of [
125I]-IgG at 30 min p.i. Data is reported as the mean 6
SEM of n=4–5 animals (***, P,0.001; **, P,0.01).
doi:10.1371/journal.pone.0034958.g006
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cell adhesion molecule ICAM-1 does not enhance anti-PECAM-1
mAb binding would argue against this scenario.
The exact mechanism of antibody-mediated collaborative
enhancement of PECAM-1 is worth further investigation. The
fact that collaborative enhancement of mAb binding occurs in vivo
implies that this phenomenon may be employed to further
optimize vascular PECAM-1 immunotargeting of diverse thera-
peutic cargoes, from anti-thrombotic agents to nanocarriers
carrying antioxidants.
Materials and Methods
Cell lines
Unless otherwise indicated, cell culture reagents were purchased
from Invitrogen (Carlsbad, CA). Human umbilical vein endothe-
lial cells (HUVECs) endogenously expressing native human
PECAM-1 (huPECAM-1) were purchased from Lonza (Walkers-
ville, MD) and maintained in EGM-2 media (Lonza) supplement-
ed with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin
(100 units/mL)/streptomycin (100 mg/mL) (P/S). Mouse pancre-
atic islet endothelial cells (MS1) cells endogenously expressing
native mouse PECAM-1 (muPECAM-1) were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and
maintained in DMEM with 10% (v/v) FBS and 1% (v/v) P/S.
Human malignant mesothelioma cells (REN) stably expressing
recombinant mouse PECAM-1 (REN-muP) [27], were maintained
in RPMI-Glutamax supplemented with 10% (v/v) FBS, 1% (v/v)
P/S, and 250 mg/mL G418.
Antibodies
Purified mAbs to huPECAM-1, mAb 62 (mouse IgG2a), and 37
(mouse IgG1), were generously provided by Dr. M. Nakada
(Centocor, Malvern, PA) [22]. Rabbit anti-mouse IgG-HRP and
mouse anti-rat IgG-HRP conjugates were purchased from
Amersham Biosciences (Pittsburg, PA). Mouse anti-FLAG-M2-
HRP mAb was purchased from Sigma-Aldrich (St-Louis, MO).
The anti-mouse PECAM-1 monoclonal antibody 390 (rat IgG2a)
[46] and MEC13.3 (rat IgG2a) [47] were purchased from BD
Bioscience (Chicago, IL) and BioLegend (San Diego, CA),
respectively. The therapeutic anti-muPECAM-1 fusion protein
390 scFv-TM (390 scFv-thrombomodulin) was produced as
previously reported [31]. The control IgG Ab was an irrelevant
mouse or rat IgG (Jackson Immunoresearch Laboratories, West
Grove, PA).
Radiolabeling of antiPECAM-1 mAbs
MAbs were directly radioiodinated using [
125I]NaI (Perkin
Elmer, Waltham, MA) and pre-coated Iodination tubes (Thermo-
fisher, Waltham, MA), and purified over a 2-mL desalting column
(Thermofisher). The radiolabeling efficiencies were 65–95%, and
the radiochemical purity, post-purification, was .95% by the
trichloroacetic acid assay. Protein concentrations were determined
by NanoDrop3000 spectrophotometer (Thermofisher) and the
specific activities of [
125I]-mAb were calculated to be 5–10 mCi/
mg.
Live-cell PECAM-1-binding assays
MAbs binding to PECAM-1 on confluent live-cell monolayers
was analyzed by Enzyme-Linked Immunosorbent Assay (ELISA),
radioimmunoassay (RIA), and co-immunoprecipitation (co-IP)
using human (HUVEC) and mouse (MS1) ECs endogenously
expressing native PECAM-1, and endothelial-like human REN-
muP cells [29] expressing recombinant muPECAM-1. Wild-type
REN cells were used as a negative control cell-line.
ELISA. Cells were grown to confluence in 1% gelatin-coated
96-well plates (BD Biosciences). Monolayers were incubated with
increasing concentration of mAbs in assay buffer (cell culture
media with 5% FBS) at 4uC for 2 h. Cells were washed twice with
assay buffer. Secondary horseradish peroxidase (HRP)-IgG
antibody conjugates were added: 1:10,000 dilution of anti-
mouse-IgG (for huPECAM-1 mAbs), anti-rat-IgG (for
muPECAM-1 mAbs), or anti-FLAG-M2-IgG (for 390 scFv-TM)
diluted in assay buffer, followed by 1 h incubation at 4uC. Cells
were washed (three times with of 3% (w/v) bovine serum albumin
(BSA)/PBS) then developed with o-phenylenediamine (OPD;
Sigma-Aldrich)/H2O2/PBS solution for 30–45 min. The
reaction was quenched with the addition of 100 mLo f5 M
H2SO4. Absorbance readings at 490 nm (OD490) were performed
on a Multiskan FC Microplate reader (Thermofisher) at room
temperature.
The modulation of muPECAM-1-targeted 390 scFv-TM
binding in the presence of self-paired parental mAb 390 or paired
mAb MEC13.3 was performed by incubating REN-muP cells with
a series dilution of 390 scFv-TM co-mixed with 22fold excess of
muPECAM-1 IgG mAbs. Data were collected as described above,
and the observed specific binding was plotted as a function of 390
scFv-TM added.
All ELISA binding data were analyzed using Prism 5.0
(GraphPad, San Diego, CA) software to determine relative
binding affinity constants, as defined by IC50. Data were fit using
equation (1) for the ‘‘four-parameter logisitic (4PL) non-linear
regression model’’ most commonly used for sigmoidal curves such
as ELISAs:
OD(X)~
ODmax{ODmin
1z
½X 50
½X 
 B zODmin ð1Þ
OD(x) is the OD490 value as a function of X, the mAb
concentration [mAb]. [X]50 is [mAb] at the inflection point of
the curve when binding is half-maximal (IC50). B is the Hill Slope
coefficient. IC50 values are reported as the mean 6 standard
deviation (SD) of three independent experiments, with each
experiment performed in triplicate.
RIA. Cells were grown to confluence in 1% gelatin-coated 96-
strip-well microplates (Corning Life Sciences, Lowell, MA). For
binding assay, monolayers of cells were incubated with increasing
concentration of [
125I]-mAb (1.8 pM–5 nM in assay buffer) in
quadruplicate at 4uC for 2 h. At the end of incubation, cells were
washed five times with ice-cold assay buffer. The cell-associated
radioactivity was measured by a gamma counter and was
normalized to the total number of cells, as counted by a
hemocytometer. Non-specific binding (NSB) was calculated by
subtracting the total binding calculated from performing the
binding assays in the presence of 1002fold excess of unlabeled
protein or by subtracting radiolabeled ligand binding to wild-type
cells. The data from the live-cell RIA experiments were analyzed
by Scatchard analysis using Prism 5.0 (GraphPad) software to
determine equilibrium binding constant and the number of
functional binding sites.
The apparent binding affinity, Kd, for specific binding was
calculated using non-linear regression analysis of a one-site
binding hyperbola:
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Bmax|½X 
½X zKd
{NSB
ð2Þ
where Bmax is the maximum number of binding sites per cell at the
asymptotic maximum; X is [mAb], and Kd is the apparent
equilibrium dissociation constant. Kd and Bmax values represent
the mean 6 SD of three or more independent experiments, and
each independent experiment was performed in quadruplicate.
The modulation of [
125I]-mAb binding in the presence of
unlabeled self-paired or paired mAb was performed by incubating
cells with a series dilution of nonlabeled mAb co-mixed with a
fixed concentration of [
125I]-mAb (0.3–0.6 nM) for 2 h at 4uCt o
allow binding. NSB was determined in the presence of 1002fold
excess of unlabeled self-paired mAb. Data were collected as
described above, and the observed specific binding was plotted as
a function of unlabeled mAb concentration. The IC50 for mAb
self-pairs and pairs was determined by fitting this data to a four-
parameter fit (see Equation 1).
Co-IP. REN-muP cells were grown to confluence in a 6 well
plate. Cells were incubated with MEC13.3 (50 nM), 390 scFv-
TM-FLAG (25 nM), or both for 30 min at 37uC and then washed
thrice to remove unbound protein. Cells were lysed at 4uC with
1 mL of RIPA buffer (Upstate, Lake Placid, NY) with protease
inhibitor (Sigma-Aldrich) and then spun at 14,0006g for 5 min.
Cell lysate supernatants were then incubated with rProtein G
Agarose Beads (Invitrogen, Carlsbad, CA) overnight at 4uCt o
precipitate mAb MEC13.3. Beads were collected by pulse
centrifugation and washed twice in ice cold RIPA buffer. Both
the cell lysates and the Protein G precipitates were analyzed by
SDS-PAGE and immunoblotting (IB). MuPECAM-1 was detected
using polyclonal goat anti-muPECAM-1 and donkey anti-goat-
HRP (both from Santa Cruz Biotech). 390 scFv-TM-FLAG was
detected with anti-FLAG-M2-HRP. MAb MEC13.3 was detected
with anti-rIgG-HRP. Control experiments were performed with
REN wild type cells where no muPECAM-1, 390 scFv-TM, or
MEC13.3 IP was detected.
RIA with immobilized protein
Soluble recombinant (r) huPECAM-1 (extracellular domain of
huPECAM-1, ,85 kDa, Antigenix America, Huntington Station,
NY), mAb 62, mAb 37, and Chrom Pure mouse IgG (mIgG,
Jackson ImmunoResearch Labs, Westgrove, PA) were coated on
plastic RIA 96-strip-well plates (0.32 cm
2/well) at a concentration
of 0.1 mg/mL (5 mg/well), overnight at 4uC. Wells were washed
thrice with 0.05% (v/v) Tween 20 (BioRad, Hercules, CA)/PBS,
and then blocked for 2 h at 4uC with 3% (w/v) BSA/PBS. Wells
were incubated with increasing concentration of [
125I]-mAb
(1.8 pM–3 nM in assay buffer) in quadruplicate at 4uC for 2 h.
An additional huPECAM-1 plate was treated with [
125I]-mAb
62+50 nM mAb 37 to evaluate the changes in apparent Kd of
[
125I]-mAb 62 with enhancer mAb treatment. At the end of
incubation, cells were washed five times with ice-cold assay buffer.
Subsequent experimental work-up and data analysis follows
similar methods to that described for live-cell RIA.
Activated protein C (APC) activity assay in live-cells
Previously reported assays of APC generation on the endothelial
cell surface [48,49] were modified to allow measurement of APC
generation by 390 scFv-TM bound to muPECAM-1 expressing
cells. REN-muP and control REN cells were grown to confluence
in 1% gelatin-coated 24-well plates (BD Biosciences). Cells were
washed with serum free media then incubated with specified
concentrations of 390 scFv-TM (622fold excess mAb MEC13.3)
for 30 min at 37uC. Cells were washed three times with assay
buffer (20 mM Tris, 100 mM NaCl, 1 mM CaCl2, 0.1% (w/v)
BSA, pH 7.5) then incubated with 1 nM bovine thrombin (Sigma-
Aldrich) and 100 nM protein C (Haematologic Technologies,
Essex Junction, VT) in assay buffer for 1 hour at 37uC. Aliquots
were removed and APC activity was measured by adding 100 nM
hirudin (to inhibit thrombin; Sigma-Aldrich) and 0.5 mM of the
APC substrate S-2366 (Diapharma, West Chester, OH). All
samples were run in duplicate. The rate of substrate hydrolysis was
measured by monitoring the change in absorbance at 405 nm over
time (mOD405/min) at room temperature using a Multiskan FC
Microplate reader. These mOD405/min values were subsequently
converted to nmol APC using a standard curve generated using
purified APC.
Animals
Wild-type C57BL/6 female mice (16–20 g) were obtained from
Jackson Laboratory (Bar Harbor, ME).
Ethics Statement
Animals were cared for and handled in accordance with the
Guide for the Care and Use of Laboratory Animals as adopted by
the NIH, under a protocol approved by the University of
Pennsylvania Institutional Animal Care and Use Committee
(IACUC). The approved protocol number was 802060.
In vivo targeting to the pulmonary endothelium
Mice were injected intravenously via jugular vein with rat
muPECAM-1 [
125I]-mAb (390 or MEC13.3) or control rat [
125I]-
IgG (n=4–5 mice per group). The injected dose was constituted in
200 mL saline with 0.3% (w/v) BSA. Organs were collected at
30 min post-injection for gamma counting (Wizard Wallac 1470,
Perkin Elmer). Data are expressed as % injected dose per gram of
tissue (% ID/g), and are reported as the mean 6 standard error of
measurement (SEM) of n=4–5 animals:
%ID=g~
(cpm in sample{cpm in background)
(sample weight)|(cpm in injected dose)
|100% ð3Þ
The pulmonary vasculature represents approximately 30% of
total endothelial surface in the body and gets preferential perfusion
by 50% of the total cardiac blood output [33], thus pulmonary
uptake of the PECAM-1 targeted [
125I]-mAb, once corrected for
blood activity, is reflective of specific mAb binding to endothelial
cells.
Data analysis and statistics
All experiments were performed at least in triplicate with a
minimum of three independent experiments. Results are expressed
as mean 6 SD unless otherwise noted. Significant differences
between means were determined using one-way ANOVA followed
by post-hoc Bonferroni multiple comparison test, or unpaired
student t-test, as appropriate. P,0.05 was considered statistically
significant. All curve fitting and statistical analyses was conducted
using Prism 5.0 software.
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Figure S1 Schematic diagram of PECAM-1 (CD31)
protein domain structure and sites of molecular binding
interactions. PECAM-1 is a 130 kDa type 1 transmembrane
glycoprotein belonging to the Ig-like superfamily of cell adhesion
molecules (CAM). It consists of six extracellular Ig C2-type
domains defined by disulfide bonds (S-S), a short transmembrane
spanning domain, and a long cytoplasmic tail containing two
ITIM [51]. Ig-domains 1 and 2 are implicated in homophilic
trans-binding interactions with endothelial PECAM-1 molecules
on adjacent cells and with PECAM-1 on circulating leukocytes. Ig-
domains 2, 3, 5, and 6 mediate heterophilic binding interactions
with other cells surface antigens (e.g. CD177 on leukocytes)
[16,52–54].
(TIF)
Figure S2 In vitro binding of muPECAM-1 mAbs 390
and MEC13.3 to live MS1 cells expressing endogenous
muPECAM-1. Cell surface binding of mAbs to native muPE-
CAM-1 on live MS1 endothelial cells was determined by an
ELISA-based method. Cells were incubated with shown concen-
trations of mAbs and incubated for 2 h at 4uC. The curves shown
are from a representative experiment. The relative binding (IC50)
of anti-PECAM-1 mAbs 390 and MEC13.3 is 0.05760.02 nM,
and 0.7260.10 nM, respectively. The IC50 is reported as the
mean IC50 value 6 SD of three independent experiments
performed in triplicate.
(TIF)
Figure S3 Modulation of [
125I]-mAb 37 binding to
huPECAM-1 in live cells by self-paired and paired anti-
PECAM-1 mAb co-incubation. The modulation of PECAM-1
binding was determined after co-incubation of [
125I]-mAb with
increasing concentrations of unlabeled self-paired mAb or paired
mAb for 2 h at 4uC. Binding data were plotted as [
125I]-mAb
bound per cell (mAb/cell) and data points were fit as described
under ‘‘Methods.’’ MAb 37 competitively inhibits self-paired
[
125I]-mAb 37 binding to HUVEC. At variance, mAb 62 does not
affect paired [
125I]-mAb 37 binding.
(TIF)
Figure S4 [
125I]-mAbs 62 and 37 bind to immobilized
rhuPECAM-1, but have no cross-reactivity with mAb 62,
mAb 37, and control mIgG. The binding of [
125I]-mAbs 62
and 37 to immobilized self-paired and paired mAb were
performed as described under ‘‘Methods.’’ RIA wells coated with
rhuPECAM-1 and mIgG served as positive and negative controls
for [
125I]-mAb 62 (A) and [
125I]-mAb 37 (A) binding, respectively.
(C) Binding data was re-plotted as [
125I]-mAb bound as % of input
at maximal input dose. [
125I]-MAbs have no difference in non-
specific binding to mAb-coated wells, whereas binding to
rhuPECAM-1 coated well is significantly higher than all IgG-
coated wells (***, P,0.001).
(TIF)
Figure S5 Modulation of [
125I]-mAb 390 and MEC13.3
binding to endogenous muPECAM-1 in live MS1 cells.
Competitive inhibition curves were obtained with self-paired
[
125I]-mAb 390/mAb 390, and [
125I]-mAb MEC13.3/mAb
MEC13.3 mixes. Collaborative binding enhancement was ob-
served for both mAb pairs, i.e., [
125I]-mAb 390/mAb MEC13.3
and [
125I]-mAb MEC13.3/mAb 390, with approximately
1.32fold and 32fold binding enhancement over solo binding,
respectively.
(TIF)
Table S1 Binding parameters of anti-PECAM-1 [
125I]-
mAbs 390 and MEC13.3 to live cells expressing mouse
PECAM-1. Binding affinity (Kd) and number of binding sites
(Bmax)o f[
125I]-mAb to REN-mPECAM-1 cells or MS1 cells. Note
that total binding was corrected for NSB using REN cells (for
REN-muP cells) or with 1002fold excess unlabeled mAb (for MS1
cells). Results were determined by three independent RIA
experiments performed in quadruplicate, with data expressed as
mean 6 S.D.
(TIF)
Table S2 Modulation of binding affinity of anti-huPE-
CAM-1 [
125I]-mAbs 62 following co-incubation with
enhancer mAb 37. Binding affinity (Kd)o f[
125I]-mAb 62 to
huPECAM-1 on live HUVECs or to immobilized rhuPECAM-1 is
studied alone or in the presence of 50 nM mAb 37. Note that total
binding was corrected for NSB using 1002fold excess unlabeled
mAb 62. Co-treatment of HUVECs with [
125I]-mAb 62 and mAb
37 led to a 1.42fold increase in binding affinity over solo binding,
whereas the binding affinity increases nearly four2fold following
collaborative enhancement with immobilized rhuPECAM-1.
Results were determined by three independent RIA experiments
performed in quadruplicate, with data expressed as mean 6 S.D.
(TIF)
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